問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
洪國竣
下載
2025-08-29 - 2031-12-31
Condition/Disease
The risk of a first major cardiovascular event is associated with elevated lipoprotein (a) (Lp[a]).
Test Drug
AMG 890 (Olpasiran)
Participate Sites9Sites
Recruiting9Sites
2025-10-01 - 2031-04-30
Patients with hereditary transthyretin transporter amyloid polyneuropathy (hATTR-PN)
Nucresiran (ALN-TTRSC04) vutrisiran (ALN-TTRSC02)
Participate Sites3Sites
Recruiting3Sites
2024-02-01 - 2026-12-31
2024-02-01 - 2028-12-31
Participate Sites11Sites
Recruiting11Sites
2021-08-31 - 2026-12-31
Participate Sites16Sites
Recruiting16Sites
2026-03-01 - 2030-10-09
Participate Sites13Sites
Not yet recruiting9Sites
Recruiting4Sites
2025-01-03 - 2028-12-31
2024-05-01 - 2029-12-31
Participate Sites10Sites
Recruiting10Sites
2024-06-01 - 2027-12-31
Participate Sites4Sites
2026-01-02 - 2029-09-30
Participate Sites6Sites
Not yet recruiting1Sites
Recruiting5Sites
全部
